Partners' Directory

  Home   Search   Join the Partnership   Login

Contact General Specializations in Countries Contribution to the Global Plan Declaration

View this partner's profile

Organization Contact Information

Name: BD
Street 1: 6th floor Signature Towers
Street 2: South City-I
City: Gurgaon
Province:
Post Code: 122001
Country: India
Phone: +919811846766
Email: lalita_shankar@bd.com
Web Site: http://www.bd.com

Focal Point Contact Information

Salutation: Dr
First Name: LALITA
Last Name: SHANKAR
Title: DIRECTOR, GLOBAL HEALTH
Email: lalita_shankar@bd.com
Phone: +919811846766

Alternate Focal Point Contact Information

Salutation: Mr
First Name: Manoj
Last Name: Gopalakrishna
Title: Managing Director
Email: manoj_gopalakrishna@bd.com
Phone: +919811846766

General Information

Board Constituency: Private sector
Organization Type - Primary: Private Sector
Organization Type - Secondary: None
Is your organization legally registered in your country: Yes
Organization Reach: International
Organization Description:
Founded in 1897, BD is an international medical technology company with operations in over 100 countries. It is the wordl's leading upplier of medical devices and a leading innovator in injection and infusion baseddrug delivery to reducethe spread of infection, enhance diabetes treament ad advance drug delivery. The BD Diagnostics segment focuses on imprving health outcomes for patients by providing laboratorieswith solutions that enhance lab system prodictivity, improve quality and inform medical devisions.
BD's rapiddiagnostic assays and microorganizm identifying and drug susceptibility systems include use of liquid based cytology systems for accurate TB diagnosis.
As a global leader in TB innovations, BD continues to support the stop TB partnrship in advocating for tigher regulation of diagnostics, increased ttention to quality ssurance in laboratories and greater engagemet of the privte sector to deliver innovative products ad approaches in India and across the world.
 
Total number of staff in your organization: 100 +
Number of full-time staff who are directly involved with TB: 100 +
Number of part-time staff who are directly involved with TB: 26 - 50
Number of volunteers who are directly involved with TB: 11 - 25
 
What is your organization's annual budget (USD) dedicated to TB? >$10 MIL
How did you hear about the Stop TB Partnership: Stop TB communications
Why do you wish join the Stop TB Partnership: Involvement in Stop TB Working Groups
 
Are you a member of a Stop TB national partnership: India
Are you in contact with your national TB programme: Yes
Please tell us how your organization is contributing to your country's national TB control plan:
BD is an active contributor to the RNTCP prgram as a private sector inducstry partner. BD's partnership with FIND which is closely associated with Govt of Inia's RNTCP program is tasked to build capacity of over 33 centers of excellence (COE) across India in accurae TB diagnosis and service delivery systems.
 

Geographical Reach

Which country is your headquarters located in: United States of America
Which WHO region is the main focus of your work: South East Asian
Which countries do you do operate in:
(This includes countries you are conducting activities in)
Argentina
Australia
Austria
Azerbaijan
Bahamas
Bangladesh
Belgium
Brazil
Cambodia
Canada
Chile
China
Colombia
Czech Republic
Democratic People's Republic of Korea
Democratic Republic of the Congo
Denmark
Dominican Republic
Ecuador
Egypt
Eritrea
Estonia
Ethiopia
Finland
France
Germany
Ghana
Greece
Guatemala
Haiti
Lao People's Democratic Republic
Malaysia
Maldives
Mexico
Monaco
Morocco
Mozambique
Namibia
Nepal
Netherlands
New Zealand
Nicaragua
Norway
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Poland
Portugal
Qatar
Republic of Korea
Republic of Montenegro
South Africa
Spain
Sri Lanka
Sudan
Sweden
Switzerland
Thailand
Trinidad and Tobago
Tunisia
Turkey
United Arab Emirates
United States of America
Uruguay
Venezuela
Viet Nam
Yemen
Zambia

Specializations

Advocacy, communication and social mobilization
Delivery of health services and care
Provision of drugs, diagnostics and commodities
Research and Development
Technical Assistance

Specializations in Countries

Provision of drugs, diagnostics and commodities Argentina
Provision of drugs, diagnostics and commodities Australia
Provision of drugs, diagnostics and commodities Austria
Provision of drugs, diagnostics and commodities Azerbaijan
Provision of drugs, diagnostics and commodities Bahamas
Provision of drugs, diagnostics and commodities Bangladesh
Provision of drugs, diagnostics and commodities Belgium
Provision of drugs, diagnostics and commodities Brazil
Provision of drugs, diagnostics and commodities Cambodia
Provision of drugs, diagnostics and commodities Canada
Provision of drugs, diagnostics and commodities Chile
Provision of drugs, diagnostics and commodities China
Provision of drugs, diagnostics and commodities Colombia
Provision of drugs, diagnostics and commodities Czech Republic
Provision of drugs, diagnostics and commodities Democratic People's Republic of Korea
Provision of drugs, diagnostics and commodities Denmark
Provision of drugs, diagnostics and commodities Dominican Republic
Provision of drugs, diagnostics and commodities Ecuador
Provision of drugs, diagnostics and commodities Egypt
Provision of drugs, diagnostics and commodities Estonia
Provision of drugs, diagnostics and commodities Ethiopia
Provision of drugs, diagnostics and commodities Finland
Provision of drugs, diagnostics and commodities France
Provision of drugs, diagnostics and commodities Germany
Provision of drugs, diagnostics and commodities Ghana
Provision of drugs, diagnostics and commodities Greece
Provision of drugs, diagnostics and commodities Guatemala
Provision of drugs, diagnostics and commodities Haiti
Provision of drugs, diagnostics and commodities Lao People's Democratic Republic
Provision of drugs, diagnostics and commodities Malaysia
Provision of drugs, diagnostics and commodities Mexico
Provision of drugs, diagnostics and commodities Monaco
Provision of drugs, diagnostics and commodities Morocco
Provision of drugs, diagnostics and commodities Namibia
Provision of drugs, diagnostics and commodities Nepal
Provision of drugs, diagnostics and commodities Netherlands
Provision of drugs, diagnostics and commodities New Zealand
Provision of drugs, diagnostics and commodities Norway
Provision of drugs, diagnostics and commodities Papua New Guinea
Provision of drugs, diagnostics and commodities Paraguay
Provision of drugs, diagnostics and commodities Peru
Provision of drugs, diagnostics and commodities Philippines
Provision of drugs, diagnostics and commodities Poland
Provision of drugs, diagnostics and commodities Portugal
Provision of drugs, diagnostics and commodities Republic of Korea
Provision of drugs, diagnostics and commodities South Africa
Provision of drugs, diagnostics and commodities Spain
Provision of drugs, diagnostics and commodities Sri Lanka
Provision of drugs, diagnostics and commodities Sweden
Provision of drugs, diagnostics and commodities Switzerland
Provision of drugs, diagnostics and commodities Thailand
Provision of drugs, diagnostics and commodities Trinidad and Tobago
Provision of drugs, diagnostics and commodities United Arab Emirates
Provision of drugs, diagnostics and commodities United States of America
Provision of drugs, diagnostics and commodities Venezuela
Provision of drugs, diagnostics and commodities Viet Nam
Provision of drugs, diagnostics and commodities Zambia

Contribution

Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below:

DOTS Expansion and Enhancement:
Atively engaged in advocacy for appropriate and accurate diagnosis andtreatment

Laboratory Strengthening:
engaed in caapcity development of Centers of excellence designated by the national TB program for better diagnosis of TB and quality assurance

New Diagnostics:
working on new technologies for diagnosis incuding use of liquid culture systems for efficient diagnosis

Declaration

Declaration of interests:
No conflicts of interest were delacred.

Application date: September 14, 2011
Last updated: September 28, 2011